Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outset Medical (OM) Accumulated Expenses (2018 - 2025)

Outset Medical (OM) has disclosed Accumulated Expenses for 7 consecutive years, with $9.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 4207.31% to $9.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.4 million, a 4207.31% increase, with the full-year FY2025 number at $9.4 million, up 4207.31% from a year prior.
  • Accumulated Expenses was $9.4 million for Q4 2025 at Outset Medical, up from $56000.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $21.5 million in Q4 2022 to a low of $56000.0 in Q3 2025.
  • A 5-year average of $7.4 million and a median of $3.7 million in 2022 define the central range for Accumulated Expenses.
  • Biggest YoY gain for Accumulated Expenses was 4207.31% in 2025; the steepest drop was 99.62% in 2025.
  • Outset Medical's Accumulated Expenses stood at $574000.0 in 2021, then skyrocketed by 3648.95% to $21.5 million in 2022, then tumbled by 82.75% to $3.7 million in 2023, then plummeted by 94.1% to $219000.0 in 2024, then soared by 4207.31% to $9.4 million in 2025.
  • Per Business Quant, the three most recent readings for OM's Accumulated Expenses are $9.4 million (Q4 2025), $56000.0 (Q3 2025), and $1.2 million (Q2 2025).